Compare Roblox Corp (RBLX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Zoetis Inc — how do they compare? Roblox Corp trades at $48.09 (market cap $32.52B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Roblox Corp and Zoetis Inc are close in size by market cap, and Zoetis Inc pays a 2.9% dividend while Roblox Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 93 Days and Zoetis Inc for 70 Days on average.
| RBLX | ZTS | |
|---|---|---|
Market Cap | $32.52B | $30.20B |
Volume | 14,552,045 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $138.56 | $147.53 |
52-Week Low | $35.54 | $69.09 |
Typical Hold Time | 93 Days | 70 Days |
Enterprise Value | $31.34B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox (RBLX) trades at $45.53, down 1.9% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company continues to demonstrate strong revenue growth, reaching $4.89 billion in 2025, but remains unprofitable with a net income margin of -17.61%. Recent analyst downgrades from Jefferies highlight concerns about bookings growth, creating mixed sentiment around the stock's near-term prospects.
While Roblox shows impressive revenue expansion and strong cash flow generation, persistent losses and high valuation metrics present significant risks. The stock faces headwinds from technical weakness and analyst skepticism, though long-term growth potential in the gaming platform remains intact. Investors must weigh the company's growth trajectory against ongoing profitability challenges.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
